Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today results from the Ph
Source: www.businesswire.com
Pfizer and Astellas Pharma have disclosed the results from its Phase 3 ARCHES trial targeting men with metastatic hormone-sensitive prostate cancer. The results showed that XTANDI (enzalutamide) plus androgen deprivation therapy met the primary endpoint by significantly reducing the risk of radiographic progression or death by 61% versus androgen deprivation therapy alone. Adverse events in the ARCHES clinical trial were consistent with those reported in enzalutamide clinical trials in patients with castration-resistant prostate cancer. Based on the ARCHES results, the companies intend to discuss these findings with global health authorities to potentially support a new indication for XTANDI in men with metastatic hormone-sensitive prostate cancer.
